Pure Laparoscopic Treatment of a Rare Giant Post-Mesenteric Benign Ovarian Seromucinous Cystadenoma: A Case Report and Literature Review
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background Ovarian seromucinous tumors, although relatively rare, represent a distinctive subset of ovarian neoplasms. These tumors are predominantly benign but carry a potential risk of malignant transformation over time. Early detection and management are crucial for improving outcomes. For large or complex masses, open surgery is preferred for better access and intraoperative histological assessment. However, with the advancement of laparoscopic techniques, minimally invasive surgery has emerged as a viable alternative for select patients, offering comparable efficacy, along with the advantages of reduced recovery times and minimal scarring. Case report: A 65-year-old female presented with a seven-month history of abdominal distension, a sensation of fullness beneath the xiphoid, left-sided discomfort, and intermittent morning cramping. Laboratory findings revealed a mild elevation in CA-125 to 46 U/mL, and CT imaging suggested a diagnosis of an ovarian cystadenoma or possibly a retroperitoneal mass. Preoperative assessment was complicated by the tumor's irregular shape, large size, and adhesions to nearby structures, making its origin unclear. A single-port laparoscopic approach was selected to minimize tissue damage, improve tumor handling, and reduce risks of fluid leakage or tumor spread. Postoperative pathology confirmed the lesion as a seromucinous ovarian cystadenoma. Conclusion This case emphasizes the need for a multidisciplinary approach in tumor diagnosis and treatment, highlighting the benefits of minimally invasive surgical techniques for better patient outcomes. Given the rarity of ovarian seromucinous tumors, continued research into their pathogenesis, classification, and treatment strategies is essential for advancing our understanding and optimizing management approaches for patients affected by these tumors.